

INTICA Biomedical, Inc.
Precision Medicine: Novel Therapeutic & Companion Diagnostic for Triple Negative Breast Cancer (NCI - Contract & Grant Recipient)
- Stage Product In Development
- Industry Biotechnology
- Location Lexington, MA, USA
- Currency USD
- Founded March 2011
- Employees 3
- Website inticabio.com
Company Summary
INTICA Biomedical, Inc. develops a combination product consisting of Targeted Therapy & Companion Diagnostic for Triple Negative Breast Cancer (TNBC). The novel drug target DEspR and its associated pathway represent true breakthrough discoveries. The NCI and the Susan G Komen Foundation are actively supporting the company's development program in TNBC.
Team
-
Vicky HerreraFounder
Professor of Medicine Boston University School of Medicine, Pediatric Cardiology, Molecular Medicine, co-discovery DEspR target, development DEspR-targeted therapy & Diagnostics
-
Christine BuntPresident, CEO & Founder
Christine Bunt is Founder and CEO of INTICA Biomedical, a new life science start-up company, currently still in stealth mode. Prior to INTICA, Christine founded TARIS Biomedical together with Prof. Michael Cima and Prof. Robert Langer from MIT, Cambridge, MA. Previously, Christine was with Merck & Co. for seven years in Whitehouse Station, NJ, where she was leading worldwide commercialization for VIOXX, MAXALT and Cardiovascular Hospital Products
-
Nelson Ruiz OpazoFounder
Professor Of Medicine Boston University, Molecular and Cell Biology, co-inventor transgenic rat atherosclerosis model, licensed to Pharmacia through NoMI, co-discovery DEspR target, development DEspR-targeted therapy & Diagnostics
-
Christopher HorvathVice President of Development
D.V.M, Lead preclinical development of 5 companies, lead IND & toxicology studies for Millenium Mabs; 6+ MAB/Protein INDs. Lead Development Taligen, Exit preclinical: $ 110 MM
-
Patrick WenAdvisory Board Member/ Dana Faber
Dr. Wen is Director of Neuro-Oncology at the Dana Faber Cancer Institure in Boston, MA. His research is focused on novel treatments of brain tumors, especially targeted molecular agents. His other clinical interests include neurologic complications of cancer. Dr. Wen is a Professor of Neurology, Harvard Medical School. Dr. Wen currently oversees more than 30 clinical trials in the fields of brain cancer/glioblastoma.
-
William LiAdvisory Board Member & Consultant
Dr. Li is President, Medical Director, and Co-founder of the Angiogenesis Foundation. Dr Li trained in the lab of Dr. Judah Folkman and has been actively engaged in angiogenesis research and clinical development for 22 years
-
Dennis AusielloChairman Scientific Advisory Board
Dr. Ausiello is the Jackson Professor of Clinical Medicine at Harvard Medical School, Chief of Medicine at Massachusetts General Hospital (MGH), and Chief Scientific Officer of Partners Healthcare. Dr. Ausiello serves as the Chairman of the Scientific Advisory Board for INTICA Biomedical.
-
George SledgeAdvisory Board Member / ASCO President
Dr. Sledge currently serves as the Ballve-Lantero Professor of Oncology and Professor of Pathology and Laboratory Medicine at the Indiana University Melvin and Bren Simon Cancer Center. Dr. Sledge is also an active member of the American Association for Cancer Research (AACR) and serves as Chairman of the Breast Cancer Committee, Hoosier Oncology Group.
-
Sangeeta BhatiaAdvisory Board Member/ MIT
Dr. Bhatia is Professor of Health Sciences and Technology and Professor of Electrical Engineering and Computer Science, MIT, Cambridge, Ma. Dr. Bhatia's research in the Laboratory for Multiscale Regenerative Technologies is focused on the applications of micro- and nanotechnology to tissue repair and regeneration. Her research includes a multidisciplinary effort to develop nanomaterials as tools for biological studies and as multifunctional agent
Advisors
-
Peter Finn (Corporate), Edward Gates (IP)LawyerUnconfirmedCFO: Eric CollardAccountantUnconfirmed
Previous Investors
-
NIH, NCI, Boston University $3.5 MM +Unconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.